PLEASANTON, Calif., Nov. 6, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025. Accessibility StatementSkip Navigation 10x Genomics expects fourth quarter 2025 revenue to be in the range of $154 million to$158 million, representing a 6% decline from the corresponding prior year period and 5% growth sequentially at the midpoint. Recent Updates "Our team delivered a solid third qu ...